CT

Chia Tai TianQing Pharmaceutical Group

China - Lianyungang
Pharmaceutical
WebsiteLinkedInCareers Page

Focus: Small Molecules, Generics

Chia Tai TianQing Pharmaceutical Group is a life sciences company focused on Small Molecules, Generics.

OncologyRespiratoryInfectious DiseasesImmunologyHematology
Open Jobs
0

Products & Portfolio (5)

DEGARELIX ACETATE
degarelix acetate
Pre-Launch
NJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
ERIBULIN MESYLATE
eribulin mesylate
Post-LOE
INTRAVENOUS · SOLUTION
aggregates. Eribulin exerts its effects via a tubulin-based antimitotic mechanism leading to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage. In addition, eribulin treatment of human breast cancer cells caused changes in morphology and gene expression as well as decreased migration and invasiveness in vitro. In mouse xenograft models of human breast cancer, eribulin treatment was associated with increased vascular perfusion and permeability in the tumor cores, resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype.
metastatic liposarcomabreast cancer
2025
30
FOSAPREPITANT DIMEGLUMINE
fosaprepitant dimeglumine
Post-LOE
INTRAVENOUS · POWDER
accordingly, its antiemetic effects are attributable to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK 1 ) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CINV). Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK 1 receptors. Animal and human studies have shown that aprepitant augments the antiemetic activity of the 5-HT 3 -receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both the acute and delayed phases of cisplatin-induced emesis.
older for the prevention of: acutedelayed nauseavomiting associated with initial+4 more
2021
30
FULVESTRANT
fulvestrant
Post-LOE
INTRAMUSCULAR · SOLUTION
Estrogen Receptor Antagonists
2020
30
PALBOCICLIB CAPSULES
palbociclib
Pre-Launch
SMCAPSULE

Pipeline & Clinical Trials

Domestic Tenofovir Disoproxil Fumarate Tablets
Chronic Hepatitis B
N/A
Clinical Trials (1)
NCT02287857Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B
N/A
Superparamagnetic Iron Oxide Nanoparticles
Coronary Artery Calcification
N/A
Clinical Trials (1)
NCT07400406A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance for the Detection of Calcified Coronary Arteries
N/A
N/A
Clinical Trials (1)
NCT04373395Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
N/A
Anlotinib Hydrochloride Capsule
Thyroid Neoplasms
N/A
Clinical Trials (1)
NCT05994365Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
N/A
Anlotinib Hydrochloride
Non-Small-Cell Lung
N/A
Clinical Trials (1)
NCT03766490Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
N/A
Group 1: single-dose of test formulation+single-dose of reference formulation
Thrombocytopenia
N/A
Clinical Trials (1)
NCT06768632Bioequivalence Test of Eltrombopag Olamine Tablets in Humans Under Fasting State
N/A
Anlotinib Hydrochloride
Non-Small Cell Lung Cancer
N/A
Clinical Trials (1)
NCT03998085Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC
N/A
Empagliflozin Tablets
Type 2 Diabetes
N/A
Clinical Trials (1)
NCT03771781Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.
N/A
L-pantoprazole sodium
Bleeding Gastric Ulcer
N/A
Clinical Trials (1)
NCT02108756Efficacy and Safety of L-Pantoprazole Sodium Injection to Treat Upper Gastrointestinal Ulcer Bleeding
N/A
Anlotinib Hydrochloride
NSCLC
N/A
Clinical Trials (1)
NCT04007835Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
N/A
Group 1: single-dose of test formulation+single-dose of reference formulation
Thrombocytopenia
N/A
Clinical Trials (1)
NCT06768619Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State
N/A
Superparamagnetic Iron Oxide Nanoparticles
Heart Aneurysm
N/A
Clinical Trials (1)
NCT06146751A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance Imaging for the Detection of Intracardiac Thrombus
N/A
Baraclude® tablets,1.0 mg
Chronic Hepatitis b
N/A
Clinical Trials (1)
NCT03847246Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers
N/A
Methacholine Choline Provocation Test
Asthma
N/A
Clinical Trials (1)
NCT05870436A Study on the Diagnostic Value of the Methacholine Choline Provocation Test in the Asthmatic Population
N/A
Methacholine Chloride
Asthma
N/A
Clinical Trials (1)
NCT05634473A Study to Evaluate the Sensitivity and Specificity of Inhaled Methacholine in Bronchial Provocation Test
N/A
mesylate imatinib capsule
Chronic Myeloid Leukemia
Phase 1
Clinical Trials (1)
NCT01795716Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
Phase 1
TQB2102 injection
Advanced Cancer
Phase 1
Clinical Trials (1)
NCT05735496Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
Phase 1
TQB2928 injection + Almonertinib Mesilate Tablets
Advanced Non-small Cell Lung Cancer
Phase 1
Clinical Trials (1)
NCT06585059Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
Phase 1
Phase 1
Clinical Trials (1)
NCT04340427A Study of TQB3455 Tablets in Subjects With Advanced Malignancies
Phase 1
Phase 1
Clinical Trials (1)
NCT02944864A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics
Phase 1
Phase 1
Clinical Trials (1)
NCT04275050A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets
Phase 1
Phase 1
Clinical Trials (1)
NCT04854681Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers
Phase 1
Phase 1
Clinical Trials (1)
NCT06522945To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects
Phase 1
TQB3909 tablets
Hematologic Malignancy
Phase 1
Clinical Trials (1)
NCT06211751A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy
Phase 1
TQB2102 for injection
Breast Cancer
Phase 1
Clinical Trials (1)
NCT06115902A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer
Phase 1
TQB2029 injection
Multiple Myeloma
Phase 1
Clinical Trials (1)
NCT06700395A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
Phase 1
TQB2618 injection azacitidine, AZA decitabine, DAC
Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase 1
Clinical Trials (1)
NCT05426798Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase 1
Anlotinib Combined With Pemetrexed And Carboplatin
Non-squamous Cell Non-Small Cell Lung Cancer
Phase 1
Clinical Trials (1)
NCT03790228Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC
Phase 1
Phase 1
Phase 1
Clinical Trials (1)
NCT04804904A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects
Phase 1
TQ05105 Tablets
Myelofibrosis
Phase 1
Clinical Trials (1)
NCT05982106To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects
Phase 1
Bevacizumab injection
Rectal Cancer
Phase 1
Clinical Trials (1)
NCT05476341A Phase I Clinical Trial of Bevacizumab Injection
Phase 1
TQB2930 injection
Advanced Cancers
Phase 1
Clinical Trials (1)
NCT05380882Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers
Phase 1
Phase 1
Clinical Trials (1)
NCT06415903A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT05046847A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors
Phase 1
Trastuzumab for injection
Metastatic Breast Cancer
Phase 1
Clinical Trials (1)
NCT05765357Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers
Phase 1
TQB2922 for injection
Advanced Cancer
Phase 1
Clinical Trials (1)
NCT06188624Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
Phase 1
TQC3564 tablets
Allergic Rhinitis
Phase 1
Clinical Trials (1)
NCT05607446To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis
Phase 1
Phase 1
Clinical Trials (1)
NCT02996838A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics
Phase 1
Phase 1
Clinical Trials (1)
NCT06672263A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia
Phase 1
domestic polysaccharide superparamagnetic iron oxide nanoparticle
Chronic Kidney Diseases
Phase 1
Clinical Trials (1)
NCT05045872Assessment of Renal Vasculature and Function with Ferumoxytol-enhanced Magnetic Resonance Imaging
Phase 1
TQH3821 tablets
Rheumatoid Arthritis
Phase 1
Clinical Trials (1)
NCT05380934A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects
Phase 1
Phase 1
Clinical Trials (1)
NCT06754891Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
Phase 1
The injectable TQD3606
Infections
Phase 1
Clinical Trials (1)
NCT05340530To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects
Phase 1
TQB3616 capsule + itraconazole
Healthy
Phase 1
Clinical Trials (1)
NCT06662773Drug-Drug Interaction (DDI) Study for TQB3616
Phase 1
Phase 1
Clinical Trials (1)
NCT05975645A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).
Phase 1
Anlotinib and 14C-labeled Anlotinib
Advanced Solid Tumors
Phase 1
Clinical Trials (1)
NCT02622932Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients
Phase 1
Subutinib Maleate capsules
Solid Tumor
Phase 1
Clinical Trials (1)
NCT01806376A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics
Phase 1
Phase 1
Clinical Trials (1)
NCT05675202Material Balance Study of TQ-B3525
Phase 1
TQB2252 injection
Advanced Cancers
Phase 1
Clinical Trials (1)
NCT06649656A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors
Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 5 approved products, 49 clinical trials
Top TAs: Oncology
Portfolio Health
Pre-Launch2 (40%)
Post-LOE3 (60%)
5 total products
Therapeutic Area Focus
Oncology
3 marketed
Marketed
Pipeline